ангиотензин受体阻断剂与杜普伊特伦病的保护性益处无关
Daniel A Portney1,2, Jacob M Johnson1,2,3, Manjot Singh1,2
1Brown University, Providence, RI, USA.
Hand (New York, N.Y.)
|June 12, 2025
概括
ангиотензинII受体阻断剂 (ARBs) 不能防止杜普伊特伦病 (DD) 的发生. 这项研究发现,与预期相反,ARB与初始和随后的DD手术的风险更高有关.
科学领域:
- 纤维增殖性疾病 纤维增殖性疾病
- 药理疗法 药理疗法 药理疗法
- 在TGF-β1路径中.
背景情况:
- 杜普伊特伦病 (Dupuytren's disease,DD) 是一种渐进性纤维扩散性疾病.
- 转化生长因子β1 (TGF-β1) 在DD的发病过程中起作用.
- ангиотензинII受体抑制剂 (ARBs) 抑制TGF-β1,并被提议用于DD治疗.
研究的目的:
- 评估ARB和杜普伊特伦病程序之间的关联.
- 评估ARB对DD复发的影响.
主要方法:
- 使用PearlDiver国家保险数据集进行患者识别.
- 创建匹配的队列来比较ARB用户与非用户的索引和随后的DD程序.
- 采用多变量逻辑回归来分析与程序相关的因素.
主要成果:
- 在ARB组 (3年) 中,指数程序的发生率高于ARB组 (21.9%),而不是对照组 (17.6%).
- 在ARB组 (22.9%) 和对照组 (18.0%) 中,后续程序率也较高.
- ARBs独立地与指数 (OR 1.32) 和后续程序 (OR 1.35) 的几率增加有关.
结论:
- 与假设相反,ARBs没有被发现对DD有保护作用.
- 研究结果表明,ARB可能与DD手术风险增加有关.
- 需要进一步的研究来理解这种意想不到的关联.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
642
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
642
01:25Antihypertensive Drugs: Direct Renin Inhibitors
513
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
513
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
145
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
145
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
541
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
541
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
564
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
564